Reishi Mushroom and Cancer: A Scientific Study Review

Reishi mushroom (Ganoderma lucidum) has generated a large body of laboratory research showing that its bioactive compounds can kill cancer cells, slow tumor growth, and boost immune function in cell cultures and animal models. But the clinical picture in humans is far less dramatic. A Cochrane systematic review, the gold standard for evidence synthesis, found that reishi given alongside conventional cancer treatment may improve tumor response rates and immune markers, yet the quality of the underlying trials was generally low, and reishi alone did not show convincing anticancer effects. The gap between what happens in a petri dish and what happens in a patient remains the central tension in this field.

The Compounds Behind the Claims

Reishi contains hundreds of biologically active molecules, but two families get the most attention in cancer research: polysaccharides and triterpenoids. The polysaccharides, especially beta-glucans, are large sugar-chain molecules that interact with immune cells. The triterpenoids, particularly a group called ganoderic acids, are the compounds most often studied for direct effects on cancer cells. Beyond these, reishi also contains peptides, proteins, and sterols that contribute to its overall pharmacological profile.¹

The polysaccharide fraction includes both alpha-1,4-glucan and beta-1,3-glucan, two structurally distinct molecules that show up consistently in fruiting body samples.² This matters because the type, size, and branching pattern of these polysaccharides can differ wildly between reishi products, which has downstream consequences for both research comparability and consumer experience.

Immune Modulation and Why It Matters for Cancer

Most cancer researchers interested in reishi start with its effects on the immune system rather than its direct toxicity to tumors. The immune system is the body’s primary surveillance network for abnormal cells, and when it functions well, it catches and destroys many cancerous cells before they ever form a detectable tumor. Reishi compounds appear to enhance several arms of this surveillance network.

A randomized, placebo-controlled trial in healthy adults found that beta-glucan derived from reishi significantly increased counts of several types of immune cells, including CD3+, CD4+, and CD8+ T-lymphocytes, as well as natural killer cells. The study also found improved natural killer cell cytotoxicity and higher levels of immunoglobulin A compared to placebo.³ Natural killer cells are one of the immune system’s first responders against tumor cells, and reishi is one of several natural products that have been shown to enhance their activity.⁴

Reishi polysaccharides also act on dendritic cells, which serve as the immune system’s alarm system. When dendritic cells encounter something suspicious, they present it to T cells, essentially telling the rest of the immune system what to attack. Lab studies have shown that reishi polysaccharides promote the maturation of dendritic cells and increase their ability to stimulate T cell responses.⁵ A separate study on human dendritic cells found that reishi polysaccharides boosted production of key signaling molecules, enhanced T cell activation, and increased T cell secretion of interferon-gamma, a cytokine important for anti-tumor immunity.⁶

There is also evidence that reishi polysaccharides modulate gut microbiota in ways that could influence immune-related disease and tumor progression, including regulating inflammatory signaling and increasing production of short-chain fatty acids that support intestinal barrier function.⁷ This line of research is still early, but it suggests that some of reishi’s immune effects might originate in the gut rather than through direct absorption of its compounds.

What Lab Studies Show Against Cancer Cells

The laboratory evidence for reishi’s anticancer properties is surprisingly broad. Researchers have tested reishi extracts and isolated compounds against lung, breast, prostate, and cervical cancer cell lines, among others, and found effects through several distinct mechanisms.

Ganoderic acids, the triterpenoid compounds, have been shown to trigger programmed cell death (apoptosis) in cancer cells while being much less toxic to healthy cells.⁸ In lung cancer cells, ganoderic acid T inhibited proliferation of a highly metastatic cell line by inducing apoptosis and arresting the cell cycle.⁹ A derivative of ganoderic acid A showed similar effects in cervical cancer cells, blocking cell cycle progression and inducing apoptosis through a specific signaling pathway.¹⁰

In prostate cancer cells, reishi extract inhibited proliferation in a dose- and time-dependent manner, arrested the cell cycle, and shifted the balance of pro-survival and pro-death proteins toward apoptosis.¹¹ Breast cancer research has been particularly active. In inflammatory breast cancer cells, reishi inhibited invasion, disrupted cell spheroids, and reduced expression of genes involved in cancer cell survival and metastasis.¹² Another study found that reishi suppressed breast cancer cell growth and migration by inhibiting a major growth signaling pathway.¹³

Beyond directly killing cancer cells, reishi compounds appear to interfere with angiogenesis, the process by which tumors grow new blood vessels to feed themselves. In prostate cancer cells, reishi inhibited the early stages of new blood vessel formation by reducing secretion of growth factors that tumors use to recruit blood supply.¹⁴ A polysaccharide-peptide fraction from reishi similarly inhibited vascular cell growth and reduced the signaling molecule VEGF in lung cancer cells under low-oxygen conditions, the exact environment found inside many solid tumors.¹⁵

One animal study stands out for testing what reishi does to metastasis, the spread of cancer from one organ to another. Oral administration of reishi extract only modestly slowed the growth of large primary tumors in mice, but it significantly reduced the number of breast-to-lung metastases. The extract downregulated genes associated with invasive behavior in the cancer cells.¹⁶ This result is noteworthy because metastasis, not the original tumor, is what kills most cancer patients. But it is still a mouse study, and the jump to human relevance remains unproven.

What the Human Clinical Trials Actually Found

The most rigorous assessment of reishi in cancer patients comes from a Cochrane systematic review that pooled data from five randomized controlled trials. The review found that patients who received reishi alongside conventional chemotherapy or radiotherapy were more likely to respond positively compared to those who received chemo or radiation alone. Immune markers also improved: the percentage of CD3, CD4, and CD8 cells increased by roughly 2 to 4 percentage points, and natural killer cell activity was marginally elevated. Four of the studies reported that patients in the reishi group had relatively improved quality of life.¹⁷

However, the same review found that reishi alone, without conventional treatment, did not demonstrate meaningful tumor regression. The review authors also flagged that the included studies were generally small, methodologically uneven, and sometimes poorly reported, so the positive results should be treated as suggestive rather than definitive.¹⁸

Not all trials have been positive. An open-label study of medical mushrooms (including reishi) in prostate cancer patients who had biochemical failure after radical treatment found no significant anticancer effects.¹⁹ That result is a useful reality check: even in a cancer type where reishi shows strong effects in the lab, the human evidence did not follow. The disconnect between petri-dish potency and clinical outcomes is not unique to reishi; it is one of the most common patterns in cancer research generally.

Effects on Quality of Life and Symptom Burden

Even when reishi does not shrink tumors, it may still help cancer patients feel better during treatment. A cross-sectional survey of over 1,100 cancer patients who experienced symptoms found that more than 80 percent reported improvement in at least one symptom after using reishi. The most commonly improved symptoms were nausea (55 percent reported meaningful improvement), fatigue (52 percent), poor appetite (51 percent), depression (50 percent), and drowsiness (49 percent).²⁰ These are self-reported outcomes, which means they are subject to placebo effects and recall bias, but the breadth of reported improvement across multiple symptoms is striking.

A pilot clinical trial in breast cancer patients undergoing endocrine therapy tested reishi spore powder specifically for cancer-related fatigue. The reishi group showed statistically significant improvements in physical well-being and fatigue scores, along with less anxiety and depression and better overall quality of life. Immune markers associated with cancer-related fatigue also improved, and no serious adverse effects were reported.²¹ As a pilot study, the sample was small, but the results align with the broader survey data suggesting that fatigue and emotional well-being are areas where reishi may offer real, if modest, support.

Safety Concerns and Drug Interactions

Reishi is generally considered well-tolerated in most studies, but “generally tolerated” is not the same as “risk-free,” and a few safety issues deserve attention, especially for cancer patients who are already on multiple medications.

The most serious reported adverse event is liver injury. A case report described a 47-year-old man who developed acute hepatitis with significant liver enzyme elevation after consuming reishi mushroom powder alongside alcohol. His symptoms and lab abnormalities resolved completely within two weeks of conservative treatment, but the case highlights that reishi is not entirely benign, particularly when combined with other liver stressors like alcohol.²²

The drug interaction picture is more complex and arguably more concerning for cancer patients. Reishi triterpenoids have been shown to inhibit several liver enzymes responsible for metabolizing many common drugs. An animal study found that reishi extract significantly inhibited CYP2B6, CYP2C9, CYP3A4, and CYP1A2 activity, increasing blood levels of drugs that are normally broken down by these enzymes.²³ The polysaccharide fraction appears to inhibit some of the same enzymes, and the effect may be dose-dependent, with different doses producing different outcomes for certain enzymes.²⁴

Why does this matter practically? Many chemotherapy drugs, targeted therapies, anti-nausea medications, pain medications, and immunosuppressants are processed by these same liver enzymes. If reishi slows down the breakdown of a chemotherapy drug, the effective dose in the patient’s blood could be higher than intended, potentially increasing both efficacy and toxicity in unpredictable ways. This is not a theoretical concern limited to reishi; it is the same mechanism behind grapefruit juice warnings on many medication labels. But the fact that both the triterpenoid and polysaccharide fractions of reishi show this inhibition means the interaction potential may be broader than for simpler supplements. Cancer patients considering reishi should discuss it with their oncologist specifically because of these enzyme interactions.

The Product Standardization Problem

One of the least-discussed but most important issues in reishi cancer research is that “reishi” in one study may bear little resemblance to “reishi” in another. The mushroom can be consumed as a dried powder, a hot-water extract, an alcohol extract, spore powder, or a purified fraction of a specific compound. Each preparation emphasizes different active components. Hot-water extraction pulls out polysaccharides preferentially. Alcohol extraction captures more triterpenoids. Spore powder contains its own distinct profile.

Growing conditions also affect the chemical output substantially. Research on liquid culture techniques has shown that optimizing factors like nitrogen availability, carbon supply, and air exposure can dramatically change the yield of specific triterpenoids, with total production of five key ganoderic acids reaching over 960 milligrams per liter under optimized laboratory conditions.²⁵ If culture conditions matter this much in a controlled laboratory, the variation between commercial products grown under uncontrolled or proprietary conditions is likely even larger.

This creates a fundamental problem for interpreting the research. A positive trial using a specific polysaccharide fraction does not mean that a capsule of ground-up reishi fruiting body from your local supplement shop will produce the same result. The Cochrane review’s difficulty in drawing strong conclusions stemmed partly from this exact issue: the studies it pooled used different preparations, different doses, and different cancer types, making comparison difficult. Until the field settles on standardized preparations and validated quality-control markers, every consumer is essentially guessing at what they are actually taking.

Where Things Stand Between Lab and Clinic

The pattern across reishi cancer research is a common one in natural product pharmacology: compelling in vitro and animal evidence, early human signals that are mostly positive but methodologically weak, and a near-total absence of the large, randomized, placebo-controlled trials that would be needed to change clinical practice. Reishi can kill cancer cells in a dish through apoptosis, cell cycle arrest, and anti-angiogenic mechanisms. It can boost immune cell counts and activity in healthy volunteers and cancer patients. It may improve quality of life for people undergoing treatment. But it has not been shown to cure cancer, extend survival, or replace any component of standard oncology care in a well-designed trial.

The review literature consistently calls for better-designed trials with standardized preparations, and that call has gone largely unanswered for over a decade. Part of the problem is economic: reishi is a natural product that cannot be patented in the way a novel drug can, which reduces the financial incentive for pharmaceutical companies to fund large trials. Part of it is the standardization challenge described above. And part of it is that the regulatory landscape for dietary supplements does not require the same proof of efficacy demanded of prescription drugs, so products continue to sell without the rigorous clinical validation that patients and oncologists would need to feel confident recommending them. For now, the honest summary is that reishi is a biologically active fungus with genuine anticancer properties in the laboratory, a plausible immune-boosting companion to conventional treatment, and an unproven therapy that should not be used as a substitute for evidence-based cancer care.